Patents by Inventor Wendelin Frick

Wendelin Frick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES
    Publication number: 20090264402
    Abstract: The invention therefore relates to the compound of the formula I or a pharmaceutically acceptable salt thereof, its pharmaceutically composition and uses.
    Type: Application
    Filed: April 30, 2009
    Publication date: October 22, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Claus-Dieter Graf, Wolfgang Schmider
  • Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
    Patent number: 7579339
    Abstract: One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: August 25, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Stefanie Flohr, Andreas Lindenschmidt, Heiner Glombik, Werner Kramer, Hubert Heuer, Hans-Ludwig Schaefer
  • Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
    Patent number: 7576200
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: August 18, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Process for the preparation of diphenyl azetidinone derivatives
    Patent number: 7563888
    Abstract: The present invention is a process for the preparation of diphenylazetidinone derivatives of the formula (I) or forms thereof comprising the substituents X, R1 and/or R2 as defined herein. More specifically, the invention comprises methods for the preparation of these compounds by cyclization of certain ?-amino carboxamides or ?-amino carboxylic esters. These diphenylazetidinone compounds are useful in the treatment of high blood serum cholesterol levels and the maintenance of the reduced cholesterol levels achieved thereby.
    Type: Grant
    Filed: November 7, 2006
    Date of Patent: July 21, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Joachim-Heiner Jendralla, Guenter Billen, Wendelin Frick, Bernd Junker, Theodor Andreas Wollman
  • Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
    Patent number: 7488829
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 10, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schäfer
  • Method for producing 1,4-diphenyl azetidinone derivatives
    Patent number: 7488818
    Abstract: The present invention is directed to the preparation of novel compounds useful in the treatment of hyperlipidemia, arteriosclerosis, hypercholesterolemia, and other related metabolic disorders. More specifically, the present invention is a novel process for the preparation of 1,4-diphenylazetidinone derivatives from ?-substituted amino amides which are protected in the presence of silylating agents and at least one cyclization catalyst whose structural formula is represented by one of the general formula: wherein the various R-groups are defined herein.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: February 10, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Andreas Lindenschmidt, David William Will, Gerhard Jaehne, Theodor Andreas Wollmann, Wendelin Frick, Bernd Junker, David Rigal, Guenter Billen, Heiner Jendralla
  • Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
    Publication number: 20080281092
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: July 17, 2008
    Publication date: November 13, 2008
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schafer
  • Phosophoinositoglycan binding proteins
    Patent number: 7449560
    Abstract: The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: November 11, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Wendelin Frick, Stefan Petry, Rudolf Schneider, Matthias Urmann
  • Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia
    Publication number: 20080274947
    Abstract: The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising diphenylazetidinones compounds which have an additional hydroxy function in the 2? position and their salts. The invention therefore relates to compounds of formula I: in which the meanings R1, R2, R3, R4, R5, R6 are defined herein.
    Type: Application
    Filed: May 19, 2008
    Publication date: November 6, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gerhard JAEHNE, Wendelin FRICK, Andreas LINDENSCHMIDT, Hubert HEUER, Hans-Ludwig SCHAEFER, Werner KRAMER, Wolfgang SCHMIDER
  • Method for isolating an intestinal cholesterol binding protein
    Patent number: 7435727
    Abstract: The invention describes a method for isolating an intestinal protein which is able to bind cholesterol and/or cholesterol uptake inhibitors. Methods of identifying inhibitors of cholesterol uptake and related pharmaceuticals and methods of treatment also are described.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: October 14, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Werner Kramer, Wendelin Frick
  • 1,4-BENZOTHIAZEPINE 1,1-DIOXIDE DERIVATIVE, PROCESS FOR ITS PREPARATION, MEDICAMENTS COMPRISING THIS COMPOUND, AND USE THEREOF AS A HYPOLIPIDAEMIC
    Publication number: 20080207534
    Abstract: The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.
    Type: Application
    Filed: January 7, 2008
    Publication date: August 28, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wendelin FRICK, Heiner GLOMBIK, Hubert HEUER, Hans-Ludwig SCHAEFER, Stefan THEIS
  • Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
    Publication number: 20080207592
    Abstract: The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic.
    Type: Application
    Filed: January 7, 2008
    Publication date: August 28, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Wendelin FRICK, Heiner GLOMBIK, Hubert HEUER, Hans-Ludwig SCHAEFER, Stefan THEIS
  • Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
    Patent number: 7407938
    Abstract: One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: August 5, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Stefanie Flohr, Andreas Lindenschmidt, Heiner Glombik, Werner Kramer, Hubert Heuer, Hans-Ludwig Schaefer
  • Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
    Patent number: 7399777
    Abstract: Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: July 15, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Eugen Falk, Wendelin Frick, Stefanie Keil, Hans-Ludwig Schäfer, Lothar Schwink, Wolfgang Wendler
  • METHOD FOR ISOLATING AN INTESTINAL CHOLESTEROL BINDING PROTEIN
    Publication number: 20080167451
    Abstract: The invention describes a method for isolating an intestinal protein which is able to bind cholesterol and/or cholesterol uptake inhibitors.
    Type: Application
    Filed: October 16, 2007
    Publication date: July 10, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Werner KRAMER, Wendelin FRICK
  • Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
    Patent number: 7390790
    Abstract: One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: June 24, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Stefanie Flohr, Andreas Lindenschmidt, Heiner Glombik, Werner Kramer, Hubert Heuer, Hans-Ludwig Schaefer
  • Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
    Patent number: 7388004
    Abstract: One embodiment of the invention relates to compounds of the formula I: in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: June 17, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Stefanie Flohr, Andreas Lindenschmidt, Heiner Glombik, Werner Kramer, Hubert Heuer, Hans-Ludwig Schaefer
  • NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF
    Publication number: 20080108580
    Abstract: Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and process for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 8, 2008
    Applicant: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin FRICK, Heiner Glombik, Werner Kramer, Hubert Heuer, Harm Brummerhop, Oliver Plettenburg
  • Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
    Patent number: 7288528
    Abstract: Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and process for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 30, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Werner Kramer, Hubert Heuer, Harm Brummerhop, Oliver Plettenburg
  • Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
    Publication number: 20070208179
    Abstract: Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
    Type: Application
    Filed: May 7, 2007
    Publication date: September 6, 2007
    Inventors: Heiner Glombik, Werner Krame, Stefanie Flohr, Wendelin Frick, Hubert Heuer, Gerhard Jaehne, Andreas Lindenschmidt, Hans-Ludwig Schafer